University of Massachusetts

Other

Celia A Schiffer

Akbar Ali

Ashley N Matthew

Linah N Rusere

Nese Kurt Yilmaz

Mina Henes

Nese Kurt-Yilmaz

Debra A Ragland

Gordon J Lockbaum

Florian Leidner

Konstantin B Zeldovich

Jacqueto Zephyr

Troy W Whitfield

Aysegul Ozen

Nageswara R Desaboini

The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.

Hepatitis c virus NS3/4A protease inhibitors

The present application provides compounds and methods of treating viral infections, including viral infections caused by HIV or HTLV.

Antiviral compounds

At least one binding site of a protein is probed by calculating a set of molecular dynamic trajectories of a protein-ligand complex family. At least one script is applied to the molecular dynamic trajectories to form a set of tensors, and at least one second script is applied to the set of tensors to integrate the set of tensors with experimental binding data corresponding to the protein-ligand complex family to form a primary image of the binding site, thereby probing the binding site of the protein.

Method for probing at least one binding site of a protein

The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof. 

Hepatitis C virus NS3/4A protease inhibitors

Growing community of inventors

Shrewsbery, MA, United States of America

Celia A Schiffer